Pim J. French
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 137 publications
Exploring the landscape of targetable alterations in patients with glioblastoma.
Journal: Nature reviews. Clinical oncology
Published: July 20, 2026
Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target.
Journal: Neuro-oncology advances
Published: January 13, 2026
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.
Journal: Cell reports. Medicine
Published: September 09, 2025
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium.
Journal: Neuro-oncology
Published: August 30, 2025
Epigenetic evolution of isocitrate dehydrogenase-wildtype glioblastomas.
Journal: Neuro-oncology
Published: August 28, 2025
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Journal: Neuro-oncology
Published: August 19, 2025
Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas.
Journal: bioRxiv : the preprint server for biology
Published: August 12, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: July 13, 2025
T cell immunity in glioma and potential implications for immunotherapy: a systematic review.
Journal: Neuro-oncology
Published: July 01, 2025
T cell immunity in glioma and potential implications for immunotherapy: A systematic review.
Journal: Neuro-oncology
Published: July 01, 2025
Last Updated: 09/26/2026